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Background: Controversy exists as to the ability of human gammaherpesviruses to cause or exacerbate breast
cancer disease in patients. The difficulty in conducting definitive human studies can be overcome by investigating
developing breast cancer in a mouse model. In this study, we utilized mice latently infected with murine
gammaherpesvirus 68 (HV-68) to question whether such a viral burden could exacerbate metastatic breast cancer
disease using a mouse mammary tumor model.
Results: Mice latently infected with HV-68 had a similar primary tumor burden, but much greater metastatic
disease, when compared to mock treated mice given the transplantable tumor, 4 T1. This was true for lung lesions,
as well as secondary tumor masses. Increased expression of pan-cytokeratin and VEGF-A in tumors from HV-68
infected mice was consistent with increased metastatic disease in these animals. Surprisingly, no viral particles could
be cultured from tumor tissues, and the presence of viral DNA or RNA transcripts could not be detected in primary
or secondary tumor tissues.
Conclusions: Latent HV-68 infection had no significant effect on the size of primary 4 T1 mammary tumors, but
exacerbated the number of metastatic lung lesions and secondary tumors when compared to mock treated mice.
Increased expression of the tumor marker, pan-cytokeratin, and VEGF-A in tumors of mice harboring latent virus
was consistent with an exacerbated metastatic disease. Mechanisms responsible for this exacerbation are indirect,
since no virus could be detected in cancerous tissues.
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An association between Epstein Barr Virus (EBV) [1]
and breast cancer continues to be controversial [2-5].
While EBV is clearly an etiologic agent in epithelial cell
cancers like nasopharyngeal carcinoma and some gastric
carcinomas [6-8], its importance in breast cancers
remains uncertain. For more than 15 years, [9], numer-
ous laboratory studies have reported the detection of
EBV genomes, EBV RNA, or viral protein in breast bi-
opsy tissues or cells [9-14]. The overriding notion for
these studies was that if EBV was detected, even in a
percentage of patients or even in a small percentage of
breast cancer cells, that a possible etiology might be* Correspondence: klbost@uncc.edu
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reproduction in any medium, provided the orindicated. Alternatively, if EBV was not detected, this
would eliminate this virus from consideration as a causa-
tive agent in breast cancers. If fact, other investigators
have not been able to detect the presence of EBV in bi-
opsied breast cancer tissues [15-20]. Thus, while it is dif-
ficult to prove such negative results due to possible
technical limitations, the lack of positive results in some
studies adds to the controversy. Even if detection meth-
ods become more sophisticated, more sensitive, and/or
more reliable, the ability to detect EBV within human
breast cancer tissue or cells would only suggest a role
for this virus in some patients due to the ethical limita-
tions of performing more definitive studies.
Less consideration has been given to the possibility
that the presence of systemic EBV in some breast can-
cer patients might indirectly exacerbate disease without
being present within the tumor cells themselves. Suchal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Morbidity of HV-68 infected mice as 4 T1 breast
tumors develop. Groups of mice (N = 10) were mock treated
(circles) or HV-68 infected (squares). Six months later mice were
injected with syngeneic 4 T1 mammary tumor cells in the mammary
fat pad. Mice were weighed and scored for morbidity following
cancer cell transplantation. Results are shown as mean values
(± standard deviations) with asterisks indicating a statistically
significant difference between groups. Numbers in parentheses
indicate the animals that remained alive when the experiment was
terminated. This study was repeated twice with similar results.
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correlated the presence of EBV in infiltrating lympho-
cytes [21], or where EBV reactivation was associated
with pregnancy [22]. Furthermore, such a suggestion is
not without precedence in disease states, since EBV-
exacerbated autoimmune disease has been investigated
for many years as an indirect result of viral infection
[23-25].
Unfortunately, due to the limitations in patient studies,
cause-effect relationships will remain difficult to prove.
Whether the presence of EBV has a direct contribution,
an indirect contribution, or no contribution to the eti-
ology, exacerbation, or increased metastasis of some
breast cancers will be difficult to define.
In the present study, we utilized an excellent mouse
model of gammaherpesvirus infection to directly address
the possibility that prior infection with an EBV-like gam-
maherpesvirus exacerbates metastases in mouse models
of breast cancer. Murine gammaherpesvirus 68 (HV-68)
mimics the pathophysiology of EBV [26,27], and has been
used as a rodent model to investigate the host-pathogen
interaction [28-33]. Upon intranasal or oral inoculation in
mice [32], there is a productive infection of epithelial cells,
followed by infection of B lymphocytes, and also macro-
phages and dendritic cells [26]. A marked leukocytosis
(i.e. mononucleosis) and splenomegaly occurs, which
peaks around 15 days post-infection and results in the es-
tablishment of latency for the life of the host. Given an ap-
propriate stimulus [34], gammaherpesviruses can emerge
from latency, resulting in a productive infection and the
re-establishment of latency. The pathophysiology of mur-
ine gammaherpesvirus 68 closely mimics that observed
for EBV infections [26,27], making this model a useful
one for investigating such viral infections.
Similarly the syngeneic, transplantable mouse mam-
mary tumor, 4 T1, which was utilized here, is a tractable
model for the study of human breast cancers [35]. In the
present study, we question whether mice latently
infected with HV-68 had increased disease when com-
pared to mock treatment. There were two surprising
findings from this work. The size of primary mammary
tumors did not differ between these two groups, how-
ever a significant increase in metastatic disease was
observed in mice harboring this latent virus. Further-
more, it is highly unlikely that this exacerbated meta-
static disease is the direct result of viral infection of
4 T1 cells since no infectious virus or viral RNA tran-
scripts could be detected in tumor tissues.
Results
Morbidity of HV-68 infected mice as 4 T1 breast tumors
develop
To assess any clinical effects that gammaherpesvirus in-
fection might have on developing breast cancer, weemployed a mouse model of HV-68 infection [26-28] and
the transplantable mammary tumor, 4 T1 [35]. Groups of
mice were mock treated or infected with HV-68. Six
months later after the virus had established latency, 4 T1
mammary tumor cells were injected into mammary fat
pads of mice. The weight and general health of the ani-
mals were recorded as the mammary tumors developed.
Approximately three weeks following mammary cell
transplantation, there was a noticeable difference in the
health of mice that were latently infected with HV-68
compared to the mock treated group. As shown in
Figure 1, weight loss was accelerated in mice with a viral
burden, and this experiment was terminated 44 days fol-
lowing transplantation when two of ten HV-68 infected
mice succumbed to metastatic disease.
Primary mammary tumor burden in mock and HV-68
infected mice
Mice were euthanized at 44 days following tumor cell
transplantation to quantify mammary tumor burden in
each animal. Figure 2A shows the average weights of
mammary tumors in mock versus HV-68 infected mice.
Since the body weights of mice in each group differed
significantly by day 44 (Figure 1), it was important to
factor in this difference when comparing tumor burden
(Figure 2B). Regardless of the method of analysis, we
could detect no significant difference in primary mam-
mary tumor burden in mock versus HV-68 infected mice.
Metastatic tumor burden in mock and HV-68 infected mice
Following euthanasia, metastatic tumor burden in per-
ipheral organs and the lungs was also assessed. When




















































Figure 2 Primary mammary tumor burden in mock and HV-68
infected mice. At death or at day 44 following tumor cell
transplantation, groups of mice (N= 10) were euthanized and
primary mammary tumor tissue excised and weighed. Panel A
shows mean tumor weights (± standard deviations). Panel B
shows the ratio of average body weight to average tumor weight
(± standard deviations) as a measure of tumor burden.
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infected mice had increased numbers of secondary
tumors. Figure 3 shows a representative example of the
average number of tumors per mouse in each group,
with 100% of HV-68 infected mice having multiple me-
tastases (Figure 3B). Similarly, lung lesions due to infil-
trating tumor cells were significantly increased in HV-68
infected mice (Figure 3C), with 100% of mice harboring
latent virus having multiple lesions (Figure 3D).
Representative histological sections are shown in
Figure 4 as evidence of the differences between lung
lesions in mock (Figures 4C and 4E) and infected mice
(Figures 4G, and 4I). In HV-68 infected mice, areas of
tumor cell accumulation were readily observed (circled
regions in Figures 4G and 4I). Higher magnifications
of these representative histological sections for mock
treated (Figures 4D and 4F) and infected mice (Figures 4H
and 4J) show similar differences in infiltrating tumor cells.
We concluded that the metastatic tumor burden in
HV-68 infected mice was significantly increased whencompared to mock treated animals (Figures 3 and 4).
These observations were consistent with the increased
weight loss and increased morbidity observed in latently
infected animals (Figure 1).
Pan-cytokeratin staining of lung and secondary tumor
sections
4 T1 cells are epithelial in origin and express high levels
of cytokeratins, allowing these proteins to mark the
presence of infiltrating tumor cells. Therefore these
proteins were used as markers for the presence of infil-
trating cancer cells in lung and tumor tissues. To
visualize 4 T1 tumor metastases in HV-68 infected
mice, sections of lung and primary tumors were stained
with an anti-pan-cytokeratin antibody. Lung sections
from two representative HV-68 infected mice showed
increased staining for cytokeratins (circled regions in
Figures 5C and 5D), when compared to a lung section
from a representative mock treated mouse (Figure 5B).
These data are consistent with an increased metastasis
of 4 T1 tumor cells into lung tissue of mice latently
infected with this gammaherpesvirus.
We also utilized pan-cytokeratin staining to identify
secondary metastatic tumor masses as being composed
of 4 T1 cells. Tumor sections from a representative
mock treated mouse (Figure 5F) and from two represen-
tative HV-68 infected mice (Figures 5G and 5H) showed
similar staining for this tumor marker.
Vascular Endothelial Growth Factor (VEGF-A) staining of
primary mammary tumor sections
Increased expression of VEGF-A within primary breast
tumors correlates with increased angiogenesis, as well as
increased metastasis to secondary sites [36,37]. Based on
the results in Figures 3, 4, and 5, we anticipated that
mice harboring latent virus would have increased VEGF-
A expression in their primary tumors. Figure 6 shows
representative primary tumor sections from two differ-
ent HV-68 infected mice (Figures 6C and 6D) or from
mock treated animals (Figures 6A and 6B). Increased in-
tensity of VEGF-A staining can be seen in these sections
(Figures 6C and 6D), which is consistent with an
increased potential for tumor cell metastasis in HV-68
infected mice.
No detectable HV-68 RNA transcripts in primary
mammary tumors or secondary metastases
One possible explanation for increased metastasis would
be the presence of gammaherpesvirus in 4 T1 cells, as
has been suggested for some EBV-associated breast can-
cers [9-14]. To address this possibility, we attempted to
culture lytic or latent virus from tumor tissue using
methods routine in our laboratories [29,30,38], with no
success (data not shown). A more sensitive, and less































































































































Figure 3 Metastatic tumor burden in mock and HV-68 infected mice. At day 44 following tumor cell transplantation, groups of mice (N = 8–
10) were euthanized. Secondary tumors, lungs, and blood were taken from each animal. Panels A and B, respectively, show the average number
of secondary tumors and percentage of mice with secondary tumors for each group (± standard deviations). Panel C and D, respectively, show
the average number of lung metastases and percentage of mice with lung metastases for each group (+ standard deviations). Asterisks indicate
statistically significant differences between groups.
Chauhan et al. Infectious Agents and Cancer 2012, 7:11 Page 4 of 11
http://www.infectagentscancer.com/content/7/1/11technically demanding, technique was then used to de-
tect viral transcripts. This very sensitive RT-PCR analysis
[29,39,40] was used to detect the presence of any viral
RNAs in primary mammary tumors and in secondary
metastases that might be present. Two separate HV-68
RNAs were selected for analysis, including an RNA spe-
cies expressed by replicating virus (ORF65), and one
expressed in cells harboring latent virus (K3). Neither
viral transcript could be detected in primary or second-
ary tumors (Figure 7). We were also unable to detect
viral DNA using a sensitive PCR technique (data not
shown) [29,39,40]. Together, these results make it highly
unlikely that the increased metastases observed in HV-
68 infected mice following 4 T1 transplantation is due to
a viral infection of these tumor cells.
Discussion
Greater than 90% of all individuals have been exposed to
EBV [1], and this exposure usually occurs relatively early
in life before the development of most breast cancers.
Based on this fact, it might be logical to conclude that
EBV could never cause or exacerbate breast cancers
since almost all patients with these tumors have been
previously exposed to the virus. The error in this logic
lies in the fact that EBV infections, and the accompanyingviral burden, can vary dramatically between individuals
[24,41-45]. It has been suggested that more recent and
sensitive methods of EBV quantification need to be uti-
lized as a prognostic tool for EBV-associated diseases
[41,42,44]. Stated simply, even though most individuals
have been exposed to EBV, each person can have very dif-
ferent latent and replicating viral burdens. Because of this
difference, it has been postulated that some individuals
will demonstrate significant immune dysregulation in their
struggle to keep such latent viral infections under control
[46-48]. If true, it is easy to imagine how EBV might be
capable of exacerbating diseases in some individuals and
not others. Such a relationship has been suggested for the
autoimmune diseases, multiple sclerosis [23,24], systemic
lupus erythematosus [24,49], and rheumatoid arthritis
[24,50], among others.
Investigating the relationship between EBV infection
and breast cancer has been the subject of numerous
investigations [2-5]. Some studies have demonstrated the
presence of EBV genes or proteins in breast cancer biop-
sies [9-14], while other studies have not detected the
virus [15-20]. One criticism of studies that have detected
EBV genes is the low level of such expression, which
questions the small percentage of tumor cells which
might harbor virus and whether virus in non-tumor cells
Figure 4 (See legend on next page.)
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Figure 4 H & E staining to visualize metastatic lung lesions in untreated, mock and HV-68 infected mice. At day 44 following tumor cell
transplantation, groups of mice (N= 8–10) were euthanized. Lungs were taken from each animal, fixed in formalin, and paraffin embedded for H
& E staining. Left panels (A, C, E, G, and I) show 20X magnification and right panels (B, D, F, H, and J) show 40X magnifications of the same
micrographs. Panels A and B show representative microscopic lung sections from an untreated mouse. Panels C, D, E and F show representative
microscopic lung sections from two mock treated mice that were transplanted with 4 T1 tumor cells. Panels G, H, I and J show representative
microscopic lung sections from two HV-68 infected mice transplanted with 4 T1 tumor cells. Circles show the location of clearly discernable
metastatic lesions in HV-68 infected mice.
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reactivity against EBV antigens with the development of
breast cancers, suggesting a recent or ongoing immune
response against this viral infection. Other studies have
suggested that there is a relationship between a subset of
very aggressive breast cancers and the presence of EBV
[51]. Whether the presence of this virus has a direct con-
tribution, an indirect contribution, or no contribution to
the etiology of breast cancers in a subset of patients
remains unclear [2-5].
Here we investigated the possibility that the presence
of a latent gammaherpesvirus might exacerbate disease
in a transplantable breast cancer using mouse models.
Combining HV-68 latency [26-28] with mice developing
4 T1 mammary tumors [35] allowed a direct analysis of
whether this gammaherpesvirus could infect breastFigure 5 Pan-cytokeratin staining of lung and secondary tumor sectio
(N = 8–10) were euthanized. Lungs and primary tumor masses were excised
and sectioned for staining with an antibody against pan-cytokeratin as a m
to detect the presence of anti-pan-cytokeratin antibody binding to tumor
microscopic lung section from a mouse transplanted with 4 T1 tumor cells
microscopic lung sections from two HV-68 infected mice transplanted with
increased staining for cytokeratins in infected mice. Pan-cytokeratin staining
being composed of 4 T1 cells. Tumor sections from a representative mock
mice (Panels G and H) showed similar staining for this tumor marker. It sho
bearing mice, there was higher background staining as evident by the seco
staining was not observed in the control for primary tumors (Figure 5E).carcinoma cells in vivo, and whether disease was exacer-
bated when compared to uninfected animals. While pri-
mary tumor growth did not vary between these groups
(Figure 2A and 2B), the health of mice infected with
HV-68 began to decline dramatically during days 30 to
44 post 4 T1 transplantation (Figure 1). When HV-68
infected mice began to succumb at day 44 (Figure 1),
the remaining mice were euthanized for analyses.
It then became apparent why HV-68 infected mice were
losing weight and were becoming moribund as meta-
static lesions in the lungs and secondary tumors
were accumulating in these animals (Figures 3 and 4).
Compared to uninfected mice, we concluded that
harboring latent HV-68 resulted in an exacerbation
of metastatic disease during developing 4 T1 mammary
tumors. Increased expression of pan-cytokeratinns. At day 44 following tumor cell transplantation, groups of mice
from the animals. Tissue was fixed in formalin, paraffin embedded,
arker for 4 T1 cells. The chromogen, DAB, stains brown and was used
cells. Panel B shows a representative anti-pan-cytokeratin stained
. Panels C and D show representative anti-pan-cytokeratin stained
4 T1 tumor cells. Circled regions in Panels C and D indicate areas of
was also used to identify secondary metastatic tumor masses as
treated mouse (Panel F) and from two representative HV-68 infected
uld be noted that due to increased mucus in lung tissues of tumor
ndary antibody-only control (Figure 5A). This increased background
Figure 6 VEGF-A staining of primary mammary tumor sections. At death or at day 44 following tumor cell transplantation, groups of mice
(N= 10) were euthanized. Primary mammary tumors were excised from each animal, fixed in formalin, paraffin embedded, and sectioned for
staining with an antibody against VEGF-A as a marker for angiogenesis. The chromogen, DAB, stains brown and was used to detect the presence
of anti-VEGF-A antibody binding. Panels A and B show representative anti-VEGF-A stained microscopic mammary tumor sections from two mock
treated mice transplanted with 4 T1 tumor cells. Panels C and D show representative anti-VEGF-A stained microscopic mammary tumor sections
from two HV-68 infected mice transplanted with 4 T1 tumor cells.
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this conclusion.
The availability of sensitive assays to detect lytic and
latent HV-68 allowed us to question whether primary or
secondary tumor tissue contained virus. Tissue homoge-
nates from tumors did not harbor latent or infectious
viral particles (data not shown) when cultured on per-
missive cell lines [29,30,38]. Neither the presence of a
representative lytic transcript (ORF 65) nor a representa-
tive latent transcript (K3) could be detected in any
tumor tissue (Figure 7). This RT-PCR assay can detect
less than one viral transcript in one microgram of total
RNA [29,39,40]. In addition, viral DNA could not be
detected (data not shown). Therefore it is highly unlikely
that HV-68 or HV-68 infected cells are present in tumor
tissues at a level that could explain the increased meta-
static disease that was observed. These results do not
support the notion that EBV exists within breast cancer
cells themselves as a mechanism for exacerbated disease.
The most likely explanation for HV-68 exacerbated
metastatic disease is an indirect one. Gammaherpes-
viruses, like EBV and HV-68, establish latency in Blymphocytes and other antigen presenting cells [1,26].
Reactivation from latency permits lytic virus to infect a
variety of cells while stimulating an immune response
that limits viral replication in immunocompetent indivi-
duals [1,26]. Whether factors expressed by virally
infected cells, or the immune response that controls viral
replication, or the immune dysregulation that permits
the virus to persist, are responsible for HV-68 induced
metastases is not presently clear. Such indirect mechan-
isms for EBV-exacerbated breast cancer disease in
patients have not been investigated. Unfortunately, such
definitive studies will be difficult to perform in patients.
However the present studies suggest a useful model for
investigating mechanisms responsible for gammaherpes-
virus-exacerbated cancer.
One possible outcome for demonstrating gammaher-
pesvirus-exacerbated disease is the notion that anti-viral
therapies would then be one co-treatment option for
some breast cancer patients. Surprisingly, there is not
much compelling data to suggest the presence of repli-
cating EBV in studies using breast cancer biopsies [2-5].
Most viral RNAs and proteins which have been detected
Primary Tumor
Secondary Metastases 























Figure 7 No detectable HV-68 RNA transcripts in primary
mammary tumors and secondary metastases. At death, or at day
44 following tumor cell transplantation, groups of mice (N = 10)
were euthanized. Primary mammary tumors and secondary
metastases were excised from each animal, and RNA extracted from
each tissue. Quantitative RT-PCR was performed to detect the
presence of one replicating HV-68 transcript (ORF65) and one latent
HV-68 transcript (K3). Results from 5 different animals (1, 2, 3, 4, 5)
are shown as amplified fragments electrophoresed on ethidium
bromide stained polyacryamide gels. The correct size of each
amplified fragment is indicated by comparison to DNA ladders run
on the same gel (Ladder). Positive controls for the amplification of
each gene were also included in each reaction (+). The presence of
GAPDH RNA was used as a positive control in each RT-PCR reaction.
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virus is not present during the course of developing
breast cancer, most anti-viral therapies would not be ef-
fective [52]. Furthermore, there have been no studies to
address the ability of developing breast cancer to induce
EBV reactivation from latency in vivo. Using this mouse
model of HV-68 infection, it will be possible to directly
address such questions. In particular, it will be important
to determine whether developing breast cancer can in-
duce gammaherpesvirus reactivation and at what times
during metastatic disease that replicative virus can be
detected. If such future studies demonstrate viral reacti-
vation during tumorigenesis, then the possibility thatanti-herpesvirus therapies might limit virus-induced ex-
acerbation of transplantable or spontaneous breast can-
cers could also be explored. Finally, the mechanisms
responsible for HV-68 induced exacerbation of meta-
static disease must be defined. While such studies would
be difficult to perform in patients, the ability to use HV-
68 as a model of gammaherpesvirus latency and reacti-
vation will allow definitive studies to be performed.
Methods
Animals
Six to eight week old female BALB/c mice (18–22 g)
were purchased from Jackson Laboratories (Bar Harbor,
ME) and housed in the vivarium in filter top cages con-
taining sterile bedding. After arrival, mice were quaran-
tined for at least five days, and fed chow and water ad
libitum. All animal experiments were in compliance with
protocols approved by the University of North Carolina
at Charlotte Animal Care and Use Committee.
Murine gammaherpesvirus-68 (HV-68)
Maintenance of viral stocks
Murine gammaherpesvirus-68 (HV-68; ATCC # VR-
1465) stocks were prepared by infecting baby hamster
kidney cells (BHK-21; ATCC # CCL-10) at a low multi-
plicity of infection (MOI), followed by preparation of
cellular lysates, as described previously [29,30,32].
Infection of animals
Groups of mice were anesthetized with isoflurane and
mock treated by intranasal instillation of saline, or
infected intranasally with 6 x 104 plaque forming units
of HV-68. At autopsy, animals were routinely screened
for the presence of viral genomes to demonstrate that
infection with virus had been successful in these animals
(data not shown).
Assay of plaque-forming units in cell lysates
Plaque-forming HV-68 was quantified by adding 1:3 ser-
ial dilutions of BHK-21 cell lysates to BALB/3 T12-3 cell
(ATCC # CCL-164) monolayers in 96-well plates. After
the monolayers were incubated with virus for 1 hr,
medium was removed and cells overlayed with 1%
Plaque Assay Agarose (BD Biosciences, San Diego, CA)
in medium with 30% fetal bovine serum. After 5–7 days
in 5% CO2, overlays were removed and cell monolayers
fixed for 1 hr with 4% formaldehyde and stained with
0.1% crystal violet. All serial dilutions were performed in
triplicate.
4 T1 cells
4 T1 cells (highly metastatic; ATCC# CRL-2539) were
used as model breast cancer cells [35]. Cells were cul-
tured in ATCC complete growth medium (RPMI 1640
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tamine, adjusted to contain 1.5 g/L sodium bicarbonate,
4.5 g/L glucose, 10 mM HEPES, 1.0 mM sodium pyru-
vate and 0.05 mM 2-mercaptoethanol).
Injection and monitoring of animals
Six months following mock treatment or HV-68 infec-
tion, mice with 4 T1 tumor cells. To produce tumors,
3.5x104 4 T1 cells in 50 ul of phosphate-buffered saline
(PBS) were injected into the right abdominal mammary
fat pad. Following injection, animals were monitored
and weighed three times a week until the last week of
the experiment, when they were monitored daily.
Histology
Lungs and primary tumors were fixed in Prefer (Ana-
tech, Battel Creek, MI) for a minimum of 24 hours post
dissection. Paraffin embedded blocks were prepared and
8-micron thick sections were cut for histology and im-
mune-staining. H&E staining was performed using a
standard protocol [53] and pan-cytokeratin and VEGF-A
staining was performed as previously described [35].
An anti-pancytokeratin antibody (Santa Cruz Biotech-
nology Inc., Santa Cruz, CA) and an anti-VEGF-A anti-
body (C-1, Santacruz Biotechnology Inc., Santa Cruz,
CA) were used at a concentration of 1:50 overnight at
40C. Dako anti-mouse IgG (Dako, North America) was
used at a concentration of 1:100 for 45 minutes at room
temperature. 3,3”- diaminobenzidine (DAB, Vector La-
boratories, Burlingame, CA) was use as the chromagen
and hematoxylin was used as a counterstain. Slides were
visualized under light microscopy at 20X magnification.
Detection of latent virus from tumor homogenates
Latent virus was quantified by adding 1:3 serial dilutions
of homogenized tissue to BALB/3 T12-3 cell monolayers
in 96-well plates. After the monolayers were incubated
with virus for 24 hr, wells were overlayed with 1% Plaque
Assay Agarose (BD Biosciences, San Diego, CA) in
medium with 30% fetal bovine serum. After 5–7 days in
5% CO2, overlays were removed, cell monolayers fixed




Five to twenty-five milligrams of tissue were suspended
in 250 μl of ice-cold PBS and homogenized briefly in
1.5 ml microfuge tubes. An equal volume of PBS con-
taining 2% SDS, 10 mM EDTA and 50 μg/ml Proteinase
K (Sigma-Aldrich, St. Louis, MO) was added and homo-
genates incubated overnight at 37oC. Nucleic acid was
extracted 2X with saturated phenol/chloroform/isoamylalcohol (25:24:1), precipitated with 2 volumes of EtOH,
and resuspended in PBS with 25 μg/ml RNase A (Sigma-
Aldrich). After incubation for 30 min at 37oC, DNA was
extracted 1X with phenol/chloroform/isoamyl alcohol,
precipitated with 2 volumes EtOH, microfuged for
10 min at 16,000 x g and washed with 75% EtOH. The
DNA pellet was air dried and resuspended in 10 mM
Tris, pH 8.0. DNA concentration was determined by ab-
sorbance at 260 nm.
Preparation of cDNA
Total RNA was isolated using Trizol (Invitrogen; Carls-
bad, CA), as previously described [29,54,55]. RNA sam-
ples were incubated with RNase-free pancreatic DNase
(RQ1 DNase, Promega, Madison, WI) as per the manu-
facturer's instructions, the RNA precipitated with EtOH
and resuspended in 50 μl of nuclease-free H2O. RNA
concentrations were determined with a Gene Spec III
spectrophotometer (Naka Instruments, Japan) using a
10 μl cuvette. For cDNA synthesis, one μg of RNA was
reverse-transcribed in the presence of random hexamers
(50 ng/μl), 10 mM dNTPs, 2.5 mM MgCl2 using
ImProm-II reverse transcriptase (Promega) in the buffer
supplied by the manufacturer. cDNA was precipitated
with one-tenth volume of 3 M sodium acetate (pH 5.2)
and 3 volumes of EtOH, and resuspended in 50 μl of nu-
clease-free H2O.
Semiquantitative PCR
Viral genomic DNA and mRNA transcript levels were
examined by PCR. For semiquantitative PCR, 100 ng of
DNA or cDNA was combined with 2.5 U of Taq poly-
merase (Promega), 0.2 mM each dNTP, 25 pmol of each
primer and PCR buffer containing 2.5 mM MgCl2 as
provided by the manufacturer. Samples were cycled
using 95° denaturation for 35 seconds, 60°C annealing
for 75 seconds and 72°C extension for 90 seconds, with
the first three cycles using extended denaturation,
annealing and extension times. PCR was for 35 cycles.
The extension time of the last cycle was for 5 min at 72°
C. Forty percent of each amplified PCR product was
electrophoresed on an ethidium bromide-stained 2%
agarose gel and photographed under UV illumination.
PCR primer sets were designed by using IDT SciTools
and purchased from IDT (Integrated DNA Technologies,
Coralville, IA). Primer sets used for amplification are as
follows:
HV-68 ORF65 (open reading frame-65 - murid herpes-
virus 4; accession no.NC_001826; 221 bp product):
Forward: 5' - ATG CTC CAG AAG AGG AAG GGA
CAC - 3'
Reverse: 5' - TTG GCA AAG ACC CAG AAG AAG
CC - 3'
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4; accession no. NC_001826; 241 bp product):
Forward: 5' - TCT CAC GGG CTA ATC CAA GGT
CAG - 3'
Reverse: 5' - GGG ACG TGG TTG CTG GTA AAT
CAC - 3'
GAPDH (glyceraldehyde-3-phosphate dehydrogenase;
accession no. NM_008084; 346 bp - exons 3 to 5):
Forward: 5' - CCA TCA CCA TCT TCC AGG AGC
GAG - 3'
Reverse: 5' – CAC AGT CTT CTG GGT GGC AGT
GAT - 3'
Statistics
Data were analyzed using GraphPad Prism 5 software
(GraphPad Software, Inc., San Diego, CA). Analyses
were performed using Student's t-test, or by one-way
analysis of variance (ANOVA) with Tukey’s Multiple
Comparison Test as post-test. Mean values are pre-
sented in the figures +/− the Standard Error of the Mean
(SEM). Results marked with an (*) were determined to
be statistically significant at P< 0.05.
Abbreviations
EBV: Epstein Barr Virus; HV-68: Murine gammaherpesvirus 68.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
The work was supported by a grant from the Mary Kay Foundation. We wish
to thank Dr. Larry Leamy for assistance in the statistical analyses of data in
Figure 1.
Authors’ contributions
VSC, DAN, and KLB conceived and helped design the study and participated
in data collection and analysis. LDR and PM helped design the study and
participated in the analysis of data. All authors participated in writing and
approving the final manuscript.
Received: 15 March 2012 Accepted: 23 April 2012
Published: 29 May 2012
References
1. Cohen JI: The biology of Epstein-Barr virus: lessons learned from the
virus and the host. Curr Opin Immunol 1999, 11(4):365–370.
2. Amarante MK, Watanabe MA: The possible involvement of virus in breast
cancer. J Cancer Res Clin Oncol 2009, 135(3):329–337.
3. Glaser SL, Hsu JL, Gulley ML: Epstein-Barr virus and breast cancer: state of
the evidence for viral carcinogenesis. Cancer Epidemiol Biomarkers Prev
2004, 13(5):688–697.
4. Hippocrate A, Oussaief L, Joab I: Possible role of EBV in breast cancer and
other unusually EBV-associated cancers. Cancer Lett 2011, 305(2):144–149.
5. Joshi D, Buehring GC: Are viruses associated with human breast cancer? Breast
Cancer Res Treat: Scrutinizing the molecular evidence; 2012.
6. Deyrup AT: Epstein-Barr virus-associated epithelial and mesenchymal
neoplasms. Hum Pathol 2008, 39(4):473–483.
7. Fukayama M: Epstein-Barr virus and gastric carcinoma. Pathol Int 2010,
60(5):337–350.
8. Kutok JL, Wang F: Spectrum of Epstein-Barr virus-associated diseases.
Annu Rev Pathol 2006, 1:375–404.9. Labrecque LG, Barnes DM, Fentiman IS, Griffin BE: Epstein-Barr virus in
epithelial cell tumors: a breast cancer study. Cancer Res 1995, 55(1):39–45.
10. Arbach H, Viglasky V, Lefeu F, Guinebretiere JM, Ramirez V, Bride N,
Boualaga N, Bauchet T, Peyrat JP, Mathieu MC, et al: Epstein-Barr virus
(EBV) genome and expression in breast cancer tissue: effect of EBV
infection of breast cancer cells on resistance to paclitaxel (Taxol). J Virol
2006, 80(2):845–853.
11. He JR, Chen LJ, Su Y, Cen YL, Tang LY, Yu DD, Chen WQ, Wang SM, Song EW,
Ren ZF: Joint effects of Epstein-Barr virus and polymorphisms in interleukin-
10 and interferon-gamma on breast cancer risk. J Infect Dis 2012, 205(1):64–71.
12. He JR, Tang LY, Yu DD, Su FX, Song EW, Lin Y, Wang SM, Lai GC, Chen WQ,
Ren ZF: Epstein-Barr virus and breast cancer: serological study in a high-
incidence area of nasopharyngeal carcinoma. Cancer Lett 2011,
309(2):128–136.
13. Joshi D, Quadri M, Gangane N, Joshi R: Association of Epstein Barr virus
infection (EBV) with breast cancer in rural Indian women. PLoS One 2009,
4(12):e8180.
14. Lorenzetti MA, De Matteo E, Gass H: Martinez Vazquez P, Lara J, Gonzalez P,
Preciado MV, Chabay PA: Characterization of Epstein Barr virus latency
pattern in Argentine breast carcinoma. PLoS One 2010, 5(10):e13603.
15. Baltzell K, Buehring GC, Krishnamurthy S, Kuerer H, Shen HM, Sison JD:
Epstein-Barr virus is seldom found in mammary epithelium of breast
cancer tissue using in situ molecular methods. Breast Cancer Res Treat
2012, 132(1):267–274.
16. Cox B, Richardson A, Graham P, Gislefoss RE, Jellum E, Rollag H: Breast
cancer, cytomegalovirus and Epstein-Barr virus: a nested case–control
study. Br J Cancer 2010, 102(11):1665–1669.
17. Murray PG: Epstein-Barr virus in breast cancer: artefact or aetiological
agent?. J Pathol 2006, 209(4):427–429.
18. Perkins RS, Sahm K, Marando C, Dickson-Witmer D, Pahnke GR, Mitchell M,
Petrelli NJ, Berkowitz IM, Soteropoulos P, Aris VM, et al: Analysis of Epstein-
Barr virus reservoirs in paired blood and breast cancer primary biopsy
specimens by real time PCR. Breast Cancer Res 2006, 8(6):R70.
19. Perrigoue JG, den Boon JA, Friedl A, Newton MA, Ahlquist P, Sugden B:
Lack of association between EBV and breast carcinoma. Cancer Epidemiol
Biomarkers Prev
2005, 14(4):809–814.
20. Richardson AK, Cox B, McCredie MR, Dite GS, Chang JH, Gertig DM, Southey MC,
Giles GG, Hopper JL: Cytomegalovirus, Epstein-Barr virus and risk of breast
cancer before age 40 years: a case–control study. Br J Cancer 2004, 90
(11):2149–2152.
21. Khan G, Philip PS, Al Ashari M, Houcinat Y, Daoud S: Localization of
Epstein-Barr virus to infiltrating lymphocytes in breast carcinomas and
not malignant cells. Exp Mol Pathol 2011, 914(1):66–470.
22. Agborsangaya CB, Lehtinen T, Toriola AT, Pukkala E, Surcel HM, Tedeschi R,
Lehtinen M: Association between Epstein-Barr virus infection and risk for
development of pregnancy-associated breast cancer: joint effect with
vitamin D?. Eur J Cancer 2011, 47(1):116–120.
23. Lunemann JD, Munz C: Epstein-Barr virus and multiple sclerosis. Current
neurology and neuroscience reports 2007, 72(3):53–258.
24. Niller HH, Wolf H, Minarovits J: Regulation and dysregulation of Epstein-Barr
virus latency: implications for the development of autoimmune diseases.
Autoimmunity 2008, 41(4):298–328.
25. Posnett DN: Herpesviruses and autoimmunity. Curr Opin Investig Drugs
2008, 9(5):505–514.
26. Barton E, Mandal P, Speck SH: Pathogenesis and host control of
gammaherpesviruses: lessons from the mouse. Annu Rev Immunol 2011,
29:351–397.
27. Rajcani J, Kudelova M: Murine herpesvirus pathogenesis: a model for the
analysis of molecular mechanisms of human gamma herpesvirus
infections. Acta Microbiol Immunol Hung 2005, 52(1):41–71.
28. Gasper-Smith N, Bost KL: Initiation of the host response against murine
gammaherpesvirus infection in immunocompetent mice. Viral Immunol
2004, 17(4):473–480.
29. Elsawa SF, Bost KL: Murine gamma-herpesvirus-68-induced IL-12
contributes to the control of latent viral burden, but also contributes to
viral-mediated leukocytosis. J Immunol 2004, 172(1):516–524.
30. Gasper-Smith N, Marriott I, Bost KL: Murine gamma-herpesvirus 68 limits
naturally occurring CD4 + CD25+ T regulatory cell activity following
infection. J Immunol
2006, 177(7):4670–4678.
Chauhan et al. Infectious Agents and Cancer 2012, 7:11 Page 11 of 11
http://www.infectagentscancer.com/content/7/1/1131. Mistrikova J, Raslova H, Mrmusova M, Kudelova M: A murine
gammaherpesvirus. Acta Virol 2000, 44(3):211–226.
32. Peacock JW, Bost KL: Infection of intestinal epithelial cells and
development of systemic disease following gastric instillation of murine
gammaherpesvirus-68. J Gen Virol 2000, 81(Pt 2):421–429.
33. Simas JP, Efstathiou S: Murine gammaherpesvirus 68: a model for the
study of gammaherpesvirus pathogenesis. Trends Microbiol 1998,
6(7):276–282.
34. Moser JM, Upton JW, Gray KS, Speck SH: Ex vivo stimulation of B cells
latently infected with gammaherpesvirus 68 triggers reactivation from
latency. J Virol 2005, 79(8):5227–5231.
35. Das Roy L, Pathangey LB, Tinder TL, Schettini JL, Gruber HE, Mukherjee P:
Breast-cancer-associated metastasis is significantly increased in a model
of autoimmune arthritis. Breast Cancer Res 2009, 11(4):R56.
36. Delli Carpini J, Karam AK, Montgomery L: Vascular endothelial growth
factor and its relationship to the prognosis and treatment of breast,
ovarian, and cervical cancer. Angiogenesis 2010, 13(1):43–58.
37. Vermeulen PB, van Golen KL, Dirix LY: Angiogenesis, lymphangiogenesis,
growth pattern, and tumor emboli in inflammatory breast cancer: a
review of the current knowledge. Cancer 2010, 116(11 Suppl):2748–2754.
38. Nelson DA, Singh SJ, Young AB, Tolbert MD, Bost KL: 3,4-
Methylenedioxymethamphetamine (MDMA) alters acute
gammaherpesvirus burden and limits interleukin 27 responses in a
mouse model of viral infection. Drug Alcohol Depend 2011,
116(1–3):211–221.
39. Gasper-Smith N, Singh S, Bost KL: Limited IL-6 production following
infection with murine gammaherpesvirus 68. Arch Virol 2006,
151(7):1423–1429.
40. Nelson DA, Petty CC, Bost KL: Infection with murine gammaherpesvirus
68 exacerbates inflammatory bowel disease in IL-10-deficient mice.
Inflamm Res 2009, 58(12):881–889.
41. Compston LI, Sarkobie F, Li C, Candotti D, Opare-Sem O, Allain JP: Multiplex
real-time PCR for the detection and quantification of latent and
persistent viral genomes in cellular or plasma blood fractions. Journal of
virological methods 2008, 151(1):47–54.
42. Gulley ML, Tang W: Using Epstein-Barr viral load assays to diagnose,
monitor, and prevent posttransplant lymphoproliferative disorder. Clin
Microbiol Rev 2010, 23(2):350–366.
43. Kimura H, Ito Y, Suzuki R, Nishiyama Y: Measuring Epstein-Barr virus (EBV)
load: the significance and application for each EBV-associated disease.
Rev Med Virol 2008, 18(5):305–319.
44. Li L, Chaudhuri A, Weintraub LA, Hsieh F, Shah S, Alexander S, Salvatierra O
Jr, Sarwal MM: Subclinical cytomegalovirus and Epstein-Barr virus viremia
are associated with adverse outcomes in pediatric renal transplantation.
Pediatr Transplant 2007, 11(2):187–195.
45. Thacker EL, Mirzaei F, Ascherio A: Infectious mononucleosis and risk for
multiple sclerosis: a meta-analysis. Ann Neurol 2006, 59(3):499–503.
46. Hislop AD, Taylor GS, Sauce D, Rickinson AB: Cellular responses to viral
infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol
2007, 25:587–617.
47. Munz C, Moormann A: Immune escape by Epstein-Barr virus associated
malignancies. Semin Cancer Biol 2008, 18(6):381–387.
48. Nikolich-Zugich J: Ageing and life-long maintenance of T-cell subsets in





50. Costenbader KH, Karlson EW: Epstein-Barr virus and rheumatoid arthritis:
is there a link? Arthritis Res Ther
2006, 8(1):204.
51. Mazouni C, Fina F, Romain S, Ouafik L, Bonnier P, Brandone JM, Martin PM:
Epstein-Barr virus as a marker of biological aggressiveness in breast
cancer. Br J Cancer
2011, 104(2):332–337.
52. Bean B: Antiviral therapy: current concepts and practices. Clin Microbiol Rev
1992, 5(2):146–182.
53. Chauhan VS, Sterka DG Jr, Gray DL, Bost KL, Marriott I: Neurogenic
exacerbation of microglial and astrocyte responses to Neisseria
meningitidis and Borrelia burgdorferi. J Immunol 2008, 180(12):8241–8249.54. Nelson DA, Marriott I, Bost KL: Expression of hemokinin 1 mRNA by
murine dendritic cells. J Neuroimmunol
2004, 155(1–2):94–102.
55. Nelson DA, Tolbert MD, Singh SJ, Bost KL: Expression of neuronal trace
amine-associated receptor (Taar) mRNAs in leukocytes. J Neuroimmunol
2007, 192(1–2):21–30.
doi:10.1186/1750-9378-7-11
Cite this article as: Chauhan et al.: Exacerbated metastatic disease in a
mouse mammary tumor model following latent gammaherpesvirus
infection. Infectious Agents and Cancer 2012 7:11.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
